生长激素对BiPAP通气治疗慢性阻塞性肺疾病影响的研究  

Effect of recombinant human growth hormone in patients of COPD with BiPAP ventilation

作　　者：贺群[1] 沈巨信[1] 李明晖[1] 钟波[1] 陈烨峰[1] 

机构地区：[1]浙江省绍兴市人民医院呼吸内科,绍兴312000

出　　处：《临床医学》2008年第8期26-27,共2页Clinical Medicine

摘　　要：目的评价基因重组生长激素(rHGH)在慢性阻塞性肺疾病(COPD)患者双相气道正压通气(BiPAP)治疗过程中的临床疗效。方法选择30例在呼吸内科住院的COPD呼吸衰竭需BiPAP无创通气的病人,随机分为rHGH组和对照组各15例,rHGH组除常规治疗外另予以rHGH8 IU/d。观察两组BiPAP通气时间、治疗期间两组病人的血浆蛋白值、细胞免疫功能及血糖的变化。结果rHGH组需BiPAP通气持续时间短于对照组,治疗后CD4、NKC活性、血浆白蛋血、转铁蛋白、前铁蛋白的浓度升高(P<0.05)。两组治疗前后的血糖值差异无统计学意义。结论rHGH可以改善COPD患者的细胞免疫功能,促进蛋白质合成,缩短BiPAP通气治疗时间。Objective To investigate the effects of recombinant human growth hormone （rHGH） in patients of chronic obstructive pulmonary disease（COPD） with noninvasion bi -level positive airway pressure （BiPAP） ventilation. Methods Thirty patients with COPD of respiratory failure with BiPAP ventilation were randomly assigned to rHGH group and control group. Patients in rHGH group were given rHGH 8 IU/d. The treatment days, the indexes of nutritional status, immunological function and blood glucose were recorded and compared between the two groups. Results The average treatment days in rHGH group was less than those in control group, P 〈 0.05. After 7 treatment days, the activity of CIM,NKC and the levels of albumin, transferrin and prealbumin levels were increased in rHGH group, P 〈 0.05. Conclusion The treatment days in rHGH group could be reduced , rHGH can improve the nutritional status and immunological function in patients with BiPAP ventilation.

关 键 词：双相气道正压通气 机械通气 生长激素 慢性阻塞性肺疾病 

分 类 号：R563.9[医药卫生—呼吸系统]